GW Pharmaceuticals PLC Result of AGM (1868E)

TIDMGWP

RNS Number : 1868E

GW Pharmaceuticals PLC

05 February 2015

GW Pharmaceuticals plc

Annual General Meeting

London, UK, 5 February 2015: GW Pharmaceuticals plc (AIM: GWP, NASDAQ: GWPH or the "Company") hereby provides notification that, at the Annual General Meeting of the Company held earlier today, all the resolutions set out in the Notice of Meeting sent to shareholders were duly proposed and passed.

Details of the proxy votes received in relation to each of the resolutions (which are more particularly described in the Notice of General Meeting) are as follows:

 
                  For           Against      Total         % of votes 
                                              votes         cast in 
                                                            favour 
---------------  ------------  -----------  ------------  ----------- 
 
 Resolution 1     188,610,381      442,520   189,430,048       99.77% 
---------------  ------------  -----------  ------------  ----------- 
 Resolution 2     166,787,225   22,143,730   189,430,048       88.28% 
---------------  ------------  -----------  ------------  ----------- 
 Resolution 3     184,440,444    4,442,827   189,430,048       97.65% 
---------------  ------------  -----------  ------------  ----------- 
 Resolution 4     185,543,236    3,490,633   189,430,048       98.15% 
---------------  ------------  -----------  ------------  ----------- 
 Resolution 5     185,536,701    3,503,180   189,430,048       98.15% 
---------------  ------------  -----------  ------------  ----------- 
 Resolution 6     188,588,260      459,857   189,430,048       99.76% 
---------------  ------------  -----------  ------------  ----------- 
 Resolution 7     188,317,170      666,484   189,430,048       99.65% 
---------------  ------------  -----------  ------------  ----------- 
 Resolution 8     169,163,586   19,713,744   189,430,048       89.56% 
---------------  ------------  -----------  ------------  ----------- 
 Resolution 9     171,245,427   17,677,511   189,430,048       90.64% 
---------------  ------------  -----------  ------------  ----------- 
 Resolution 10    169,148,070   19,678,474   189,430,048       89.58% 
---------------  ------------  -----------  ------------  ----------- 
 

Proxy forms which gave the Chairman and other officers of the Company discretion have been included in the "For" total.

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex(R), which is approved for the treatment of spasticity due to multiple sclerosis in 27 countries outside the United States. Sativex is also in Phase 3 clinical development as a potential treatment of pain associated with advanced cancer. GW is also advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex(R), which is in Phase 2/3 clinical development for the treatment of Dravet syndrome and which is also expected to enter Phase 3 clinical trials in the treatment of Lennox-Gastaut syndrome. GW has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 clinical development for glioma, ulcerative colitis, type 2 diabetes, and schizophrenia. For further information, please visit www.gwpharm.com.

Enquiries:

 
GW Pharmaceuticals plc 
Stephen Schultz, VP Investor         917 280 2424 / 401 
 Relations                            500 6570 
 
  FTI Consulting (Media enquiries) 
Ben Atwell / Simon Conway 
 / John Dineen                       + 44 20 3727 1000 
Robert Stanislaro (U.S.)             212 850 5657 
 
  Trout Group, LLC (US investor 
  relations) 
Todd James / Chad Rubin              646 378 2900 
 
  Peel Hunt LLP (UK NOMAD) 
James Steel / Clare Terlouw          [phone] 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGUVUSRVAAURAR